secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2026-08-12T10:45:36+00:00
Accession:  0001104659-26-094411
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia posts Q2 2026 net income of $74.7M; YUTREPIA sales surge to $170.4M
----------------------------------------------------------------------------

- YUTREPIA net sales $170.4M in Q2 2026, up 31% from Q1 2026; Q2 2025 product sales were $6.5M.
- Net income $74.7M ($0.84 basic / $0.74 diluted EPS) vs. net loss of $41.6M in Q2 2025.
- Adjusted EBITDA $96.3M; cash and equivalents $284.2M at June 30, 2026, up from $190.7M at year-end 2025.
- ~5,900 unique patient prescriptions and >5,000 patients started on YUTREPIA since June 2025 launch; >1,100 prescribers.
- Enrollment underway in Re-Spire, pivotal study for L606; 10 clinical studies progressing across known and new indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926094411/0001104659-26-094411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926094411/tm2622888d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer